Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report
Lorlatinib is an essential drug for controlling brain metastases in <i>ALK</i>-positive NSCLC. However, it can induce psychotic symptoms. When psychiatrists are involved in managing adverse effects during cancer treatment, close collaboration among oncologists, psychiatrists, and patients is essential.
Authors
- Kadoaki Ohashi (ORCID: https://orcid.org/0000-0002-5180-3933)
- Yuko Nakamura (ORCID: https://orcid.org/0000-0003-3128-4731)
- Manabu Takaki (ORCID: https://orcid.org/0000-0002-7371-2821)
- Masaki Fujiwara (ORCID: https://orcid.org/0000-0002-6181-3166)
- Shinji Sakamoto (ORCID: https://orcid.org/0000-0001-5498-551X)
- Akiyoshi Yokode
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences Reports
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/pcn5.70091
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Health, Labour and Welfare